Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Pascal Chanu
Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma
CPT: Pharmacometrics and Systems Pharmacology
Modeling
Simulation
Cardiovascular Medicine
Pharmacology
Cardiology
Exposure–Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-C-Met Antibody Onartuzumab (MetMAb) in the Second- And Third-Line Non-Small Cell Lung Cancer
AAPS Journal
Pharmaceutical Science
Related publications
Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin
British Journal of Haematology
Hematology
Polatuzumab Vedotin: First Global Approval
Drugs
Pharmacology
Epidemiology of Chemotherapy-Induced Anemia in Patients With Non-Hodgkin Lymphoma
Permanente journal,The
Medicine
Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma
OncoTargets and Therapy
Oncology
Pharmacology
Non-Hodgkin Lymphoma
Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Polatuzumab Vedotin (Pola) + Obinutuzumab (G) + Lenalidomide (Len) in Patients (Pts) With Relapsed/Refractory (R/R) Follicular Lymphoma (Fl): Phase Ib/Ii Interim Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Correction To: Polatuzumab Vedotin: First Global Approval
Drugs
Pharmacology
Longitudinal Risk of Herpes Zoster in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy: A Nationwide Population-Based Study
Scientific Reports
Multidisciplinary
